Pharma & Healthcare
Global Irritable Bowel Syndrome (IBS) Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
- Jun 11, 25
- ID: 301471
- Pages: 120
- Figures: 126
- Views: 1
In 2024, the global market size of Irritable Bowel Syndrome (IBS) was estimated to be worth US$ 6252 million and is forecast to reach approximately US$ 16410 million by 2031 with a CAGR of 15.0% during the forecast period 2025-2031.
Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.
North America is the largest region of Irritable Bowel Syndrome (IBS), with a market share about 75%. Allergan, Valeant Pharmaceuticals, Takeda, Sucampo Pharmaceuticals and McNeil Consumer Healthcare are the top 5 manufacturers of industry, and they had about 80% combined market share.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Irritable Bowel Syndrome (IBS), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Irritable Bowel Syndrome (IBS).
The Irritable Bowel Syndrome (IBS) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Irritable Bowel Syndrome (IBS) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Irritable Bowel Syndrome (IBS) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Bausch Health
Allergan
Takeda
Sucampo Pharmaceuticals (Mallinckrodt)
Sebela Pharmaceuticals Inc
Astellas Pharmaceuticals
Segment by Type
IBS-D Drug
IBS-C Drug
Others
Segment by Application
Women
Men
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Irritable Bowel Syndrome (IBS) in global and regional level.
Chapter 3: Detailed analysis of Irritable Bowel Syndrome (IBS) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Irritable Bowel Syndrome (IBS) revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.
North America is the largest region of Irritable Bowel Syndrome (IBS), with a market share about 75%. Allergan, Valeant Pharmaceuticals, Takeda, Sucampo Pharmaceuticals and McNeil Consumer Healthcare are the top 5 manufacturers of industry, and they had about 80% combined market share.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Irritable Bowel Syndrome (IBS), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Irritable Bowel Syndrome (IBS).
The Irritable Bowel Syndrome (IBS) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Irritable Bowel Syndrome (IBS) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Irritable Bowel Syndrome (IBS) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Bausch Health
Allergan
Takeda
Sucampo Pharmaceuticals (Mallinckrodt)
Sebela Pharmaceuticals Inc
Astellas Pharmaceuticals
Segment by Type
IBS-D Drug
IBS-C Drug
Others
Segment by Application
Women
Men
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Irritable Bowel Syndrome (IBS) in global and regional level.
Chapter 3: Detailed analysis of Irritable Bowel Syndrome (IBS) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Irritable Bowel Syndrome (IBS) revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
1 Study Coverage
1.1 Irritable Bowel Syndrome (IBS) Product Introduction
1.2 Market by Type
1.2.1 Global Irritable Bowel Syndrome (IBS) Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 IBS-D Drug
1.2.3 IBS-C Drug
1.2.4 Others
1.3 Market by Application
1.3.1 Global Irritable Bowel Syndrome (IBS) Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Women
1.3.3 Men
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Irritable Bowel Syndrome (IBS) Market Size Estimates and Forecasts
2.2 Irritable Bowel Syndrome (IBS) Market Size by Region: 2024 Versus 2031
2.2.1 Global Irritable Bowel Syndrome (IBS) Revenue by Region: 2020-2025
2.2.2 Global Irritable Bowel Syndrome (IBS) Revenue Forecast by Region (2026-2031)
2.2.3 Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2031)
3.1.2 Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2031)
3.2.2 Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 IBS-D Drug of Irritable Bowel Syndrome (IBS) Revenue Market Share by Application
3.3.2 IBS-C Drug of Irritable Bowel Syndrome (IBS) Revenue Market Share by Application
3.3.3 Others of Irritable Bowel Syndrome (IBS) Revenue Market Share by Application
4 Global Irritable Bowel Syndrome (IBS) by Company
4.1 Global Irritable Bowel Syndrome (IBS) Revenue by Company (2020-2025)
4.2 Global Irritable Bowel Syndrome (IBS) Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Irritable Bowel Syndrome (IBS) Companies around the World: Ranking by Revenue
4.3.2 Global Irritable Bowel Syndrome (IBS) Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Irritable Bowel Syndrome (IBS) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Irritable Bowel Syndrome (IBS) Companies Headquarters & Product Type
4.4.1 Global Irritable Bowel Syndrome (IBS) Companies Headquarters
4.4.2 Date of International Companies Enter into Irritable Bowel Syndrome (IBS) Market
4.4.3 Global Irritable Bowel Syndrome (IBS) Companies Product & Service
4.4.4 IBS-D Drug Revenue Market Share of Irritable Bowel Syndrome (IBS) by Company
4.4.5 IBS-C Drug Revenue Market Share of Irritable Bowel Syndrome (IBS) by Company
4.4.6 Others Revenue Market Share of Irritable Bowel Syndrome (IBS) by Company
4.5 Global Irritable Bowel Syndrome (IBS) Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Bausch Health
5.1.1 Bausch Health Corporation Information
5.1.2 Bausch Health Description, Business Overview
5.1.3 Bausch Health Irritable Bowel Syndrome (IBS) Products Offered
5.1.4 Bausch Health Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2020-2025)
5.1.5 Bausch Health Irritable Bowel Syndrome (IBS) Revenue by Product in 2024
5.1.6 Bausch Health Irritable Bowel Syndrome (IBS) Revenue by Application in 2024
5.1.7 Bausch Health Irritable Bowel Syndrome (IBS) Revenue by Geographic Area in 2024
5.1.8 Bausch Health Recent Developments
5.2 Allergan
5.2.1 Allergan Corporation Information
5.2.2 Allergan Description, Business Overview
5.2.3 Allergan Irritable Bowel Syndrome (IBS) Products Offered
5.2.4 Allergan Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2020-2025)
5.2.5 Allergan Irritable Bowel Syndrome (IBS) Revenue by Product in 2024
5.2.6 Allergan Irritable Bowel Syndrome (IBS) Revenue by Application in 2024
5.2.7 Allergan Irritable Bowel Syndrome (IBS) Revenue by Geographic Area in 2024
5.2.8 Allergan Recent Developments
5.3 Takeda
5.3.1 Takeda Corporation Information
5.3.2 Takeda Description, Business Overview
5.3.3 Takeda Irritable Bowel Syndrome (IBS) Products Offered
5.3.4 Takeda Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2020-2025)
5.3.5 Takeda Irritable Bowel Syndrome (IBS) Revenue by Product in 2024
5.3.6 Takeda Irritable Bowel Syndrome (IBS) Revenue by Application in 2024
5.3.7 Takeda Irritable Bowel Syndrome (IBS) Revenue by Geographic Area in 2024
5.3.8 Takeda Recent Developments
5.4 Sucampo Pharmaceuticals (Mallinckrodt)
5.4.1 Sucampo Pharmaceuticals (Mallinckrodt) Corporation Information
5.4.2 Sucampo Pharmaceuticals (Mallinckrodt) Description, Business Overview
5.4.3 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Products Offered
5.4.4 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2020-2025)
5.4.5 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue by Product in 2024
5.4.6 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue by Application in 2024
5.4.7 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue by Geographic Area in 2024
5.4.8 Sucampo Pharmaceuticals (Mallinckrodt) Recent Developments
5.5 Sebela Pharmaceuticals Inc
5.5.1 Sebela Pharmaceuticals Inc Corporation Information
5.5.2 Sebela Pharmaceuticals Inc Description, Business Overview
5.5.3 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Products Offered
5.5.4 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2020-2025)
5.5.5 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue by Product in 2024
5.5.6 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue by Application in 2024
5.5.7 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue by Geographic Area in 2024
5.5.8 Sebela Pharmaceuticals Inc Recent Developments
5.6 Astellas Pharmaceuticals
5.6.1 Astellas Pharmaceuticals Corporation Information
5.6.2 Astellas Pharmaceuticals Description, Business Overview
5.6.3 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Products Offered
5.6.4 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2020-2025)
5.6.5 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue by Product in 2024
5.6.6 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue by Application in 2024
5.6.7 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue by Geographic Area in 2024
5.6.8 Astellas Pharmaceuticals Recent Developments
6 North America
6.1 North America Irritable Bowel Syndrome (IBS) Market Size YoY Growth 2020-2031
6.2 North America Irritable Bowel Syndrome (IBS) Market Facts & Figures by Country (2020-2031)
6.3 North America Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2025)
6.4 North America Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Irritable Bowel Syndrome (IBS) Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Irritable Bowel Syndrome (IBS) Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2025)
7.4 Asia-Pacific Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2025)
8 Europe
8.1 Europe Irritable Bowel Syndrome (IBS) Market Size YoY Growth 2020-2031
8.2 Europe Irritable Bowel Syndrome (IBS) Market Facts & Figures by Country (2020-2031)
8.3 Europe Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2025)
8.4 Europe Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Irritable Bowel Syndrome (IBS) Market Size YoY Growth 2020-2031
9.2 Latin America Irritable Bowel Syndrome (IBS) Market Facts & Figures by Country (2020-2031)
9.3 Latin America Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2025)
9.4 Latin America Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Irritable Bowel Syndrome (IBS) Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Irritable Bowel Syndrome (IBS) Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2025)
10.4 Middle East and Africa Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Irritable Bowel Syndrome (IBS) Supply Chain Analysis
11.2 Irritable Bowel Syndrome (IBS) Key Raw Materials and Upstream Suppliers
11.3 Irritable Bowel Syndrome (IBS) Clients Analysis
11.4 Irritable Bowel Syndrome (IBS) Sales Channel and Sales Model Analysis
11.4.1 Irritable Bowel Syndrome (IBS) Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Irritable Bowel Syndrome (IBS) Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Irritable Bowel Syndrome (IBS) Distributors
12 Irritable Bowel Syndrome (IBS) Market Dynamics
12.1 Irritable Bowel Syndrome (IBS) Industry Trends
12.2 Irritable Bowel Syndrome (IBS) Market Drivers
12.3 Irritable Bowel Syndrome (IBS) Market Challenges
12.4 Irritable Bowel Syndrome (IBS) Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
1.1 Irritable Bowel Syndrome (IBS) Product Introduction
1.2 Market by Type
1.2.1 Global Irritable Bowel Syndrome (IBS) Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 IBS-D Drug
1.2.3 IBS-C Drug
1.2.4 Others
1.3 Market by Application
1.3.1 Global Irritable Bowel Syndrome (IBS) Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Women
1.3.3 Men
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Irritable Bowel Syndrome (IBS) Market Size Estimates and Forecasts
2.2 Irritable Bowel Syndrome (IBS) Market Size by Region: 2024 Versus 2031
2.2.1 Global Irritable Bowel Syndrome (IBS) Revenue by Region: 2020-2025
2.2.2 Global Irritable Bowel Syndrome (IBS) Revenue Forecast by Region (2026-2031)
2.2.3 Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2031)
3.1.2 Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2031)
3.2.2 Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 IBS-D Drug of Irritable Bowel Syndrome (IBS) Revenue Market Share by Application
3.3.2 IBS-C Drug of Irritable Bowel Syndrome (IBS) Revenue Market Share by Application
3.3.3 Others of Irritable Bowel Syndrome (IBS) Revenue Market Share by Application
4 Global Irritable Bowel Syndrome (IBS) by Company
4.1 Global Irritable Bowel Syndrome (IBS) Revenue by Company (2020-2025)
4.2 Global Irritable Bowel Syndrome (IBS) Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Irritable Bowel Syndrome (IBS) Companies around the World: Ranking by Revenue
4.3.2 Global Irritable Bowel Syndrome (IBS) Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Irritable Bowel Syndrome (IBS) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Irritable Bowel Syndrome (IBS) Companies Headquarters & Product Type
4.4.1 Global Irritable Bowel Syndrome (IBS) Companies Headquarters
4.4.2 Date of International Companies Enter into Irritable Bowel Syndrome (IBS) Market
4.4.3 Global Irritable Bowel Syndrome (IBS) Companies Product & Service
4.4.4 IBS-D Drug Revenue Market Share of Irritable Bowel Syndrome (IBS) by Company
4.4.5 IBS-C Drug Revenue Market Share of Irritable Bowel Syndrome (IBS) by Company
4.4.6 Others Revenue Market Share of Irritable Bowel Syndrome (IBS) by Company
4.5 Global Irritable Bowel Syndrome (IBS) Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Bausch Health
5.1.1 Bausch Health Corporation Information
5.1.2 Bausch Health Description, Business Overview
5.1.3 Bausch Health Irritable Bowel Syndrome (IBS) Products Offered
5.1.4 Bausch Health Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2020-2025)
5.1.5 Bausch Health Irritable Bowel Syndrome (IBS) Revenue by Product in 2024
5.1.6 Bausch Health Irritable Bowel Syndrome (IBS) Revenue by Application in 2024
5.1.7 Bausch Health Irritable Bowel Syndrome (IBS) Revenue by Geographic Area in 2024
5.1.8 Bausch Health Recent Developments
5.2 Allergan
5.2.1 Allergan Corporation Information
5.2.2 Allergan Description, Business Overview
5.2.3 Allergan Irritable Bowel Syndrome (IBS) Products Offered
5.2.4 Allergan Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2020-2025)
5.2.5 Allergan Irritable Bowel Syndrome (IBS) Revenue by Product in 2024
5.2.6 Allergan Irritable Bowel Syndrome (IBS) Revenue by Application in 2024
5.2.7 Allergan Irritable Bowel Syndrome (IBS) Revenue by Geographic Area in 2024
5.2.8 Allergan Recent Developments
5.3 Takeda
5.3.1 Takeda Corporation Information
5.3.2 Takeda Description, Business Overview
5.3.3 Takeda Irritable Bowel Syndrome (IBS) Products Offered
5.3.4 Takeda Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2020-2025)
5.3.5 Takeda Irritable Bowel Syndrome (IBS) Revenue by Product in 2024
5.3.6 Takeda Irritable Bowel Syndrome (IBS) Revenue by Application in 2024
5.3.7 Takeda Irritable Bowel Syndrome (IBS) Revenue by Geographic Area in 2024
5.3.8 Takeda Recent Developments
5.4 Sucampo Pharmaceuticals (Mallinckrodt)
5.4.1 Sucampo Pharmaceuticals (Mallinckrodt) Corporation Information
5.4.2 Sucampo Pharmaceuticals (Mallinckrodt) Description, Business Overview
5.4.3 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Products Offered
5.4.4 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2020-2025)
5.4.5 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue by Product in 2024
5.4.6 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue by Application in 2024
5.4.7 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue by Geographic Area in 2024
5.4.8 Sucampo Pharmaceuticals (Mallinckrodt) Recent Developments
5.5 Sebela Pharmaceuticals Inc
5.5.1 Sebela Pharmaceuticals Inc Corporation Information
5.5.2 Sebela Pharmaceuticals Inc Description, Business Overview
5.5.3 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Products Offered
5.5.4 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2020-2025)
5.5.5 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue by Product in 2024
5.5.6 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue by Application in 2024
5.5.7 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue by Geographic Area in 2024
5.5.8 Sebela Pharmaceuticals Inc Recent Developments
5.6 Astellas Pharmaceuticals
5.6.1 Astellas Pharmaceuticals Corporation Information
5.6.2 Astellas Pharmaceuticals Description, Business Overview
5.6.3 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Products Offered
5.6.4 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2020-2025)
5.6.5 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue by Product in 2024
5.6.6 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue by Application in 2024
5.6.7 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue by Geographic Area in 2024
5.6.8 Astellas Pharmaceuticals Recent Developments
6 North America
6.1 North America Irritable Bowel Syndrome (IBS) Market Size YoY Growth 2020-2031
6.2 North America Irritable Bowel Syndrome (IBS) Market Facts & Figures by Country (2020-2031)
6.3 North America Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2025)
6.4 North America Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Irritable Bowel Syndrome (IBS) Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Irritable Bowel Syndrome (IBS) Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2025)
7.4 Asia-Pacific Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2025)
8 Europe
8.1 Europe Irritable Bowel Syndrome (IBS) Market Size YoY Growth 2020-2031
8.2 Europe Irritable Bowel Syndrome (IBS) Market Facts & Figures by Country (2020-2031)
8.3 Europe Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2025)
8.4 Europe Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Irritable Bowel Syndrome (IBS) Market Size YoY Growth 2020-2031
9.2 Latin America Irritable Bowel Syndrome (IBS) Market Facts & Figures by Country (2020-2031)
9.3 Latin America Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2025)
9.4 Latin America Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Irritable Bowel Syndrome (IBS) Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Irritable Bowel Syndrome (IBS) Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2025)
10.4 Middle East and Africa Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Irritable Bowel Syndrome (IBS) Supply Chain Analysis
11.2 Irritable Bowel Syndrome (IBS) Key Raw Materials and Upstream Suppliers
11.3 Irritable Bowel Syndrome (IBS) Clients Analysis
11.4 Irritable Bowel Syndrome (IBS) Sales Channel and Sales Model Analysis
11.4.1 Irritable Bowel Syndrome (IBS) Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Irritable Bowel Syndrome (IBS) Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Irritable Bowel Syndrome (IBS) Distributors
12 Irritable Bowel Syndrome (IBS) Market Dynamics
12.1 Irritable Bowel Syndrome (IBS) Industry Trends
12.2 Irritable Bowel Syndrome (IBS) Market Drivers
12.3 Irritable Bowel Syndrome (IBS) Market Challenges
12.4 Irritable Bowel Syndrome (IBS) Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global Irritable Bowel Syndrome (IBS) Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Irritable Bowel Syndrome (IBS) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Irritable Bowel Syndrome (IBS) Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Irritable Bowel Syndrome (IBS) Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Irritable Bowel Syndrome (IBS) Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global Irritable Bowel Syndrome (IBS) Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global Irritable Bowel Syndrome (IBS) Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. Irritable Bowel Syndrome (IBS) Revenue by Company (2020-2025) & (US$ Million)
Table 11. Irritable Bowel Syndrome (IBS) Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top Irritable Bowel Syndrome (IBS) Players by Revenue (US$ Million) in 2024
Table 13. Global Irritable Bowel Syndrome (IBS) Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global Irritable Bowel Syndrome (IBS) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Irritable Bowel Syndrome (IBS) as of 2024)
Table 15. Global Irritable Bowel Syndrome (IBS) Companies Headquarters
Table 16. Date of International Companies Enter into Irritable Bowel Syndrome (IBS) Market
Table 17. Global Irritable Bowel Syndrome (IBS) Companies Product & Service
Table 18. Global Irritable Bowel Syndrome (IBS) Mergers & Acquisitions, Expansion Plans
Table 19. Bausch Health Corporation Information
Table 20. Bausch Health Description and Business Overview
Table 21. Bausch Health Irritable Bowel Syndrome (IBS) Product
Table 22. Bausch Health Irritable Bowel Syndrome (IBS) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. Bausch Health Revenue Proportion of Irritable Bowel Syndrome (IBS) by Product in 2024
Table 24. Bausch Health Revenue Proportion of Irritable Bowel Syndrome (IBS) by Application in 2024
Table 25. Bausch Health Revenue Proportion of Irritable Bowel Syndrome (IBS) by Geographic Area in 2024
Table 26. Bausch Health Recent Developments
Table 27. Allergan Corporation Information
Table 28. Allergan Description and Business Overview
Table 29. Allergan Irritable Bowel Syndrome (IBS) Product
Table 30. Allergan Irritable Bowel Syndrome (IBS) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. Allergan Revenue Proportion of Irritable Bowel Syndrome (IBS) by Product in 2024
Table 32. Allergan Revenue Proportion of Irritable Bowel Syndrome (IBS) by Application in 2024
Table 33. Allergan Revenue Proportion of Irritable Bowel Syndrome (IBS) by Geographic Area in 2024
Table 34. Allergan Recent Developments
Table 35. Takeda Corporation Information
Table 36. Takeda Description and Business Overview
Table 37. Takeda Irritable Bowel Syndrome (IBS) Product
Table 38. Takeda Irritable Bowel Syndrome (IBS) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Takeda Revenue Proportion of Irritable Bowel Syndrome (IBS) by Product in 2024
Table 40. Takeda Revenue Proportion of Irritable Bowel Syndrome (IBS) by Application in 2024
Table 41. Takeda Revenue Proportion of Irritable Bowel Syndrome (IBS) by Geographic Area in 2024
Table 42. Takeda Recent Developments
Table 43. Sucampo Pharmaceuticals (Mallinckrodt) Corporation Information
Table 44. Sucampo Pharmaceuticals (Mallinckrodt) Description and Business Overview
Table 45. Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Product
Table 46. Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Sucampo Pharmaceuticals (Mallinckrodt) Revenue Proportion of Irritable Bowel Syndrome (IBS) by Product in 2024
Table 48. Sucampo Pharmaceuticals (Mallinckrodt) Revenue Proportion of Irritable Bowel Syndrome (IBS) by Application in 2024
Table 49. Sucampo Pharmaceuticals (Mallinckrodt) Revenue Proportion of Irritable Bowel Syndrome (IBS) by Geographic Area in 2024
Table 50. Sucampo Pharmaceuticals (Mallinckrodt) Recent Developments
Table 51. Sebela Pharmaceuticals Inc Corporation Information
Table 52. Sebela Pharmaceuticals Inc Description and Business Overview
Table 53. Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Product
Table 54. Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. Sebela Pharmaceuticals Inc Revenue Proportion of Irritable Bowel Syndrome (IBS) by Product in 2024
Table 56. Sebela Pharmaceuticals Inc Revenue Proportion of Irritable Bowel Syndrome (IBS) by Application in 2024
Table 57. Sebela Pharmaceuticals Inc Revenue Proportion of Irritable Bowel Syndrome (IBS) by Geographic Area in 2024
Table 58. Sebela Pharmaceuticals Inc Recent Developments
Table 59. Astellas Pharmaceuticals Corporation Information
Table 60. Astellas Pharmaceuticals Description and Business Overview
Table 61. Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Product
Table 62. Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. Astellas Pharmaceuticals Revenue Proportion of Irritable Bowel Syndrome (IBS) by Product in 2024
Table 64. Astellas Pharmaceuticals Revenue Proportion of Irritable Bowel Syndrome (IBS) by Application in 2024
Table 65. Astellas Pharmaceuticals Revenue Proportion of Irritable Bowel Syndrome (IBS) by Geographic Area in 2024
Table 66. Astellas Pharmaceuticals Recent Developments
Table 67. North America Irritable Bowel Syndrome (IBS) Revenue by Country (2020-2025) & (US$ Million)
Table 68. North America Irritable Bowel Syndrome (IBS) Revenue by Country (2026-2031) & (US$ Million)
Table 69. North America Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2025) & (US$ Million)
Table 70. North America Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2025) & (US$ Million)
Table 71. Asia-Pacific Irritable Bowel Syndrome (IBS) Revenue by Region (2020-2025) & (US$ Million)
Table 72. Asia-Pacific Irritable Bowel Syndrome (IBS) Revenue by Region (2026-2031) & (US$ Million)
Table 73. Asia-Pacific Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2025) & (US$ Million)
Table 74. Asia-Pacific Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2025) & (US$ Million)
Table 75. Europe Irritable Bowel Syndrome (IBS) Revenue by Country (2020-2025) & (US$ Million)
Table 76. Europe Irritable Bowel Syndrome (IBS) Revenue by Country (2026-2031) & (US$ Million)
Table 77. Europe Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2025) & (US$ Million)
Table 78. Europe Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2025) & (US$ Million)
Table 79. Latin America Irritable Bowel Syndrome (IBS) Revenue by Country (2020-2025) & (US$ Million)
Table 80. Latin America Irritable Bowel Syndrome (IBS) Revenue by Country (2026-2031) & (US$ Million)
Table 81. Latin America Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2025) & (US$ Million)
Table 82. Latin America Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2025) & (US$ Million)
Table 83. Middle East and Africa Irritable Bowel Syndrome (IBS) Revenue by Country (2020-2025) & (US$ Million)
Table 84. Middle East and Africa Irritable Bowel Syndrome (IBS) Revenue by Country (2026-2031) & (US$ Million)
Table 85. Middle East and Africa Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2025) & (US$ Million)
Table 86. Middle East and Africa Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2025) & (US$ Million)
Table 87. Irritable Bowel Syndrome (IBS) Key Raw Materials, Industry Status and Trend
Table 88. Irritable Bowel Syndrome (IBS) Key Raw Materials and Upstream Suppliers
Table 89. Irritable Bowel Syndrome (IBS) Clients Status and Trend
Table 90. Irritable Bowel Syndrome (IBS) Typical Clients
Table 91. Irritable Bowel Syndrome (IBS) Distributors
Table 92. Irritable Bowel Syndrome (IBS) Market Trends
Table 93. Irritable Bowel Syndrome (IBS) Market Drivers
Table 94. Irritable Bowel Syndrome (IBS) Market Challenges
Table 95. Irritable Bowel Syndrome (IBS) Market Restraints
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Irritable Bowel Syndrome (IBS) Product Picture
Figure 2. Global Irritable Bowel Syndrome (IBS) Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Type in 2024 & 2031
Figure 4. IBS-D Drug Product Picture
Figure 5. IBS-C Drug Product Picture
Figure 6. Others Product Picture
Figure 7. Global Irritable Bowel Syndrome (IBS) Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 8. Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Application in 2024 & 2031
Figure 9. Women
Figure 10. Men
Figure 11. Irritable Bowel Syndrome (IBS) Report Years Considered
Figure 12. Global Irritable Bowel Syndrome (IBS) Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Irritable Bowel Syndrome (IBS) Market Size (2020-2031) & (US$ Million)
Figure 14. Global Irritable Bowel Syndrome (IBS) Market Size Market Share by Region: 2024 Versus 2031
Figure 15. Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Region (2020-2031)
Figure 16. Global Irritable Bowel Syndrome (IBS) Revenue Market Share Forecast by Type (2020-2031)
Figure 17. Global Irritable Bowel Syndrome (IBS) Revenue Market Share Forecast by Application (2020-2031)
Figure 18. IBS-D Drug of Irritable Bowel Syndrome (IBS) Revenue Market Share by Application, 2024 VS 2031
Figure 19. IBS-C Drug of Irritable Bowel Syndrome (IBS) Revenue Market Share by Application, 2024 VS 2031
Figure 20. Others of Irritable Bowel Syndrome (IBS) Revenue Market Share by Application, 2024 VS 2031
Figure 21. Irritable Bowel Syndrome (IBS) Revenue Share by Company (2024)
Figure 22. Irritable Bowel Syndrome (IBS) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23. IBS-D Drug Revenue Proportion by Company in 2024
Figure 24. IBS-C Drug Revenue Proportion by Company in 2024
Figure 25. Others Revenue Proportion by Company in 2024
Figure 26. North America Irritable Bowel Syndrome (IBS) Revenue 2020-2031 (US$ Million)
Figure 27. North America Irritable Bowel Syndrome (IBS) Revenue Market Share by Type (2020-2025)
Figure 28. North America Irritable Bowel Syndrome (IBS) Revenue Market Share by Application (2020-2025)
Figure 29. Asia-Pacific Irritable Bowel Syndrome (IBS) Revenue 2020-2031 (US$ Million)
Figure 30. Asia-Pacific Irritable Bowel Syndrome (IBS) Revenue Market Share by Region (2020-2031)
Figure 31. Asia-Pacific Irritable Bowel Syndrome (IBS) Revenue Market Share by Type (2020-2025)
Figure 32. Asia-Pacific Irritable Bowel Syndrome (IBS) Revenue Market Share by Application (2020-2025)
Figure 33. Europe Irritable Bowel Syndrome (IBS) Revenue Growth Rate 2020-2031 (US$ Million)
Figure 34. Europe Irritable Bowel Syndrome (IBS) Revenue Market Share by Country (2020-2031)
Figure 35. Europe Irritable Bowel Syndrome (IBS) Revenue Market Share by Type (2020-2025)
Figure 36. Europe Irritable Bowel Syndrome (IBS) Revenue Market Share by Application (2020-2025)
Figure 37. Latin America Irritable Bowel Syndrome (IBS) Revenue Growth Rate 2020-2031 (US$ Million)
Figure 38. Latin America Irritable Bowel Syndrome (IBS) Revenue Market Share by Country (2020-2031)
Figure 39. Latin America Irritable Bowel Syndrome (IBS) Revenue Market Share by Type (2020-2025)
Figure 40. Latin America Irritable Bowel Syndrome (IBS) Revenue Market Share by Application (2020-2025)
Figure 41. Middle East and Africa Irritable Bowel Syndrome (IBS) Revenue Growth Rate 2020-2031 (US$ Million)
Figure 42. Middle East and Africa Irritable Bowel Syndrome (IBS) Revenue Market Share by Country (2020-2031)
Figure 43. Middle East and Africa Irritable Bowel Syndrome (IBS) Revenue Market Share by Type (2020-2025)
Figure 44. Middle East and Africa Irritable Bowel Syndrome (IBS) Revenue Market Share by Application (2020-2025)
Figure 45. Irritable Bowel Syndrome (IBS) Supply Chain (Upstream and Downstream Market)
Figure 46. Global Production Market Share of Irritable Bowel Syndrome (IBS) Raw Materials by Region in 2024
Figure 47. Irritable Bowel Syndrome (IBS) Distribution Channels
Figure 48. Global Irritable Bowel Syndrome (IBS) Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 49. Global Irritable Bowel Syndrome (IBS) Percentage 2020-2031: Online Sales VS Offline Sales
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
Table 1. Global Irritable Bowel Syndrome (IBS) Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Irritable Bowel Syndrome (IBS) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Irritable Bowel Syndrome (IBS) Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Irritable Bowel Syndrome (IBS) Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Irritable Bowel Syndrome (IBS) Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global Irritable Bowel Syndrome (IBS) Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global Irritable Bowel Syndrome (IBS) Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. Irritable Bowel Syndrome (IBS) Revenue by Company (2020-2025) & (US$ Million)
Table 11. Irritable Bowel Syndrome (IBS) Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top Irritable Bowel Syndrome (IBS) Players by Revenue (US$ Million) in 2024
Table 13. Global Irritable Bowel Syndrome (IBS) Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global Irritable Bowel Syndrome (IBS) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Irritable Bowel Syndrome (IBS) as of 2024)
Table 15. Global Irritable Bowel Syndrome (IBS) Companies Headquarters
Table 16. Date of International Companies Enter into Irritable Bowel Syndrome (IBS) Market
Table 17. Global Irritable Bowel Syndrome (IBS) Companies Product & Service
Table 18. Global Irritable Bowel Syndrome (IBS) Mergers & Acquisitions, Expansion Plans
Table 19. Bausch Health Corporation Information
Table 20. Bausch Health Description and Business Overview
Table 21. Bausch Health Irritable Bowel Syndrome (IBS) Product
Table 22. Bausch Health Irritable Bowel Syndrome (IBS) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. Bausch Health Revenue Proportion of Irritable Bowel Syndrome (IBS) by Product in 2024
Table 24. Bausch Health Revenue Proportion of Irritable Bowel Syndrome (IBS) by Application in 2024
Table 25. Bausch Health Revenue Proportion of Irritable Bowel Syndrome (IBS) by Geographic Area in 2024
Table 26. Bausch Health Recent Developments
Table 27. Allergan Corporation Information
Table 28. Allergan Description and Business Overview
Table 29. Allergan Irritable Bowel Syndrome (IBS) Product
Table 30. Allergan Irritable Bowel Syndrome (IBS) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. Allergan Revenue Proportion of Irritable Bowel Syndrome (IBS) by Product in 2024
Table 32. Allergan Revenue Proportion of Irritable Bowel Syndrome (IBS) by Application in 2024
Table 33. Allergan Revenue Proportion of Irritable Bowel Syndrome (IBS) by Geographic Area in 2024
Table 34. Allergan Recent Developments
Table 35. Takeda Corporation Information
Table 36. Takeda Description and Business Overview
Table 37. Takeda Irritable Bowel Syndrome (IBS) Product
Table 38. Takeda Irritable Bowel Syndrome (IBS) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Takeda Revenue Proportion of Irritable Bowel Syndrome (IBS) by Product in 2024
Table 40. Takeda Revenue Proportion of Irritable Bowel Syndrome (IBS) by Application in 2024
Table 41. Takeda Revenue Proportion of Irritable Bowel Syndrome (IBS) by Geographic Area in 2024
Table 42. Takeda Recent Developments
Table 43. Sucampo Pharmaceuticals (Mallinckrodt) Corporation Information
Table 44. Sucampo Pharmaceuticals (Mallinckrodt) Description and Business Overview
Table 45. Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Product
Table 46. Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Sucampo Pharmaceuticals (Mallinckrodt) Revenue Proportion of Irritable Bowel Syndrome (IBS) by Product in 2024
Table 48. Sucampo Pharmaceuticals (Mallinckrodt) Revenue Proportion of Irritable Bowel Syndrome (IBS) by Application in 2024
Table 49. Sucampo Pharmaceuticals (Mallinckrodt) Revenue Proportion of Irritable Bowel Syndrome (IBS) by Geographic Area in 2024
Table 50. Sucampo Pharmaceuticals (Mallinckrodt) Recent Developments
Table 51. Sebela Pharmaceuticals Inc Corporation Information
Table 52. Sebela Pharmaceuticals Inc Description and Business Overview
Table 53. Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Product
Table 54. Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. Sebela Pharmaceuticals Inc Revenue Proportion of Irritable Bowel Syndrome (IBS) by Product in 2024
Table 56. Sebela Pharmaceuticals Inc Revenue Proportion of Irritable Bowel Syndrome (IBS) by Application in 2024
Table 57. Sebela Pharmaceuticals Inc Revenue Proportion of Irritable Bowel Syndrome (IBS) by Geographic Area in 2024
Table 58. Sebela Pharmaceuticals Inc Recent Developments
Table 59. Astellas Pharmaceuticals Corporation Information
Table 60. Astellas Pharmaceuticals Description and Business Overview
Table 61. Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Product
Table 62. Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. Astellas Pharmaceuticals Revenue Proportion of Irritable Bowel Syndrome (IBS) by Product in 2024
Table 64. Astellas Pharmaceuticals Revenue Proportion of Irritable Bowel Syndrome (IBS) by Application in 2024
Table 65. Astellas Pharmaceuticals Revenue Proportion of Irritable Bowel Syndrome (IBS) by Geographic Area in 2024
Table 66. Astellas Pharmaceuticals Recent Developments
Table 67. North America Irritable Bowel Syndrome (IBS) Revenue by Country (2020-2025) & (US$ Million)
Table 68. North America Irritable Bowel Syndrome (IBS) Revenue by Country (2026-2031) & (US$ Million)
Table 69. North America Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2025) & (US$ Million)
Table 70. North America Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2025) & (US$ Million)
Table 71. Asia-Pacific Irritable Bowel Syndrome (IBS) Revenue by Region (2020-2025) & (US$ Million)
Table 72. Asia-Pacific Irritable Bowel Syndrome (IBS) Revenue by Region (2026-2031) & (US$ Million)
Table 73. Asia-Pacific Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2025) & (US$ Million)
Table 74. Asia-Pacific Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2025) & (US$ Million)
Table 75. Europe Irritable Bowel Syndrome (IBS) Revenue by Country (2020-2025) & (US$ Million)
Table 76. Europe Irritable Bowel Syndrome (IBS) Revenue by Country (2026-2031) & (US$ Million)
Table 77. Europe Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2025) & (US$ Million)
Table 78. Europe Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2025) & (US$ Million)
Table 79. Latin America Irritable Bowel Syndrome (IBS) Revenue by Country (2020-2025) & (US$ Million)
Table 80. Latin America Irritable Bowel Syndrome (IBS) Revenue by Country (2026-2031) & (US$ Million)
Table 81. Latin America Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2025) & (US$ Million)
Table 82. Latin America Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2025) & (US$ Million)
Table 83. Middle East and Africa Irritable Bowel Syndrome (IBS) Revenue by Country (2020-2025) & (US$ Million)
Table 84. Middle East and Africa Irritable Bowel Syndrome (IBS) Revenue by Country (2026-2031) & (US$ Million)
Table 85. Middle East and Africa Irritable Bowel Syndrome (IBS) Revenue by Type (2020-2025) & (US$ Million)
Table 86. Middle East and Africa Irritable Bowel Syndrome (IBS) Revenue by Application (2020-2025) & (US$ Million)
Table 87. Irritable Bowel Syndrome (IBS) Key Raw Materials, Industry Status and Trend
Table 88. Irritable Bowel Syndrome (IBS) Key Raw Materials and Upstream Suppliers
Table 89. Irritable Bowel Syndrome (IBS) Clients Status and Trend
Table 90. Irritable Bowel Syndrome (IBS) Typical Clients
Table 91. Irritable Bowel Syndrome (IBS) Distributors
Table 92. Irritable Bowel Syndrome (IBS) Market Trends
Table 93. Irritable Bowel Syndrome (IBS) Market Drivers
Table 94. Irritable Bowel Syndrome (IBS) Market Challenges
Table 95. Irritable Bowel Syndrome (IBS) Market Restraints
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Irritable Bowel Syndrome (IBS) Product Picture
Figure 2. Global Irritable Bowel Syndrome (IBS) Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Type in 2024 & 2031
Figure 4. IBS-D Drug Product Picture
Figure 5. IBS-C Drug Product Picture
Figure 6. Others Product Picture
Figure 7. Global Irritable Bowel Syndrome (IBS) Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 8. Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Application in 2024 & 2031
Figure 9. Women
Figure 10. Men
Figure 11. Irritable Bowel Syndrome (IBS) Report Years Considered
Figure 12. Global Irritable Bowel Syndrome (IBS) Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Irritable Bowel Syndrome (IBS) Market Size (2020-2031) & (US$ Million)
Figure 14. Global Irritable Bowel Syndrome (IBS) Market Size Market Share by Region: 2024 Versus 2031
Figure 15. Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Region (2020-2031)
Figure 16. Global Irritable Bowel Syndrome (IBS) Revenue Market Share Forecast by Type (2020-2031)
Figure 17. Global Irritable Bowel Syndrome (IBS) Revenue Market Share Forecast by Application (2020-2031)
Figure 18. IBS-D Drug of Irritable Bowel Syndrome (IBS) Revenue Market Share by Application, 2024 VS 2031
Figure 19. IBS-C Drug of Irritable Bowel Syndrome (IBS) Revenue Market Share by Application, 2024 VS 2031
Figure 20. Others of Irritable Bowel Syndrome (IBS) Revenue Market Share by Application, 2024 VS 2031
Figure 21. Irritable Bowel Syndrome (IBS) Revenue Share by Company (2024)
Figure 22. Irritable Bowel Syndrome (IBS) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23. IBS-D Drug Revenue Proportion by Company in 2024
Figure 24. IBS-C Drug Revenue Proportion by Company in 2024
Figure 25. Others Revenue Proportion by Company in 2024
Figure 26. North America Irritable Bowel Syndrome (IBS) Revenue 2020-2031 (US$ Million)
Figure 27. North America Irritable Bowel Syndrome (IBS) Revenue Market Share by Type (2020-2025)
Figure 28. North America Irritable Bowel Syndrome (IBS) Revenue Market Share by Application (2020-2025)
Figure 29. Asia-Pacific Irritable Bowel Syndrome (IBS) Revenue 2020-2031 (US$ Million)
Figure 30. Asia-Pacific Irritable Bowel Syndrome (IBS) Revenue Market Share by Region (2020-2031)
Figure 31. Asia-Pacific Irritable Bowel Syndrome (IBS) Revenue Market Share by Type (2020-2025)
Figure 32. Asia-Pacific Irritable Bowel Syndrome (IBS) Revenue Market Share by Application (2020-2025)
Figure 33. Europe Irritable Bowel Syndrome (IBS) Revenue Growth Rate 2020-2031 (US$ Million)
Figure 34. Europe Irritable Bowel Syndrome (IBS) Revenue Market Share by Country (2020-2031)
Figure 35. Europe Irritable Bowel Syndrome (IBS) Revenue Market Share by Type (2020-2025)
Figure 36. Europe Irritable Bowel Syndrome (IBS) Revenue Market Share by Application (2020-2025)
Figure 37. Latin America Irritable Bowel Syndrome (IBS) Revenue Growth Rate 2020-2031 (US$ Million)
Figure 38. Latin America Irritable Bowel Syndrome (IBS) Revenue Market Share by Country (2020-2031)
Figure 39. Latin America Irritable Bowel Syndrome (IBS) Revenue Market Share by Type (2020-2025)
Figure 40. Latin America Irritable Bowel Syndrome (IBS) Revenue Market Share by Application (2020-2025)
Figure 41. Middle East and Africa Irritable Bowel Syndrome (IBS) Revenue Growth Rate 2020-2031 (US$ Million)
Figure 42. Middle East and Africa Irritable Bowel Syndrome (IBS) Revenue Market Share by Country (2020-2031)
Figure 43. Middle East and Africa Irritable Bowel Syndrome (IBS) Revenue Market Share by Type (2020-2025)
Figure 44. Middle East and Africa Irritable Bowel Syndrome (IBS) Revenue Market Share by Application (2020-2025)
Figure 45. Irritable Bowel Syndrome (IBS) Supply Chain (Upstream and Downstream Market)
Figure 46. Global Production Market Share of Irritable Bowel Syndrome (IBS) Raw Materials by Region in 2024
Figure 47. Irritable Bowel Syndrome (IBS) Distribution Channels
Figure 48. Global Irritable Bowel Syndrome (IBS) Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 49. Global Irritable Bowel Syndrome (IBS) Percentage 2020-2031: Online Sales VS Offline Sales
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Medical Waste Fluid Solidifier Market Research Report 2025
Jun 12, 25
Global Metalized Bubble Material Market Research Report 2025
Jun 12, 25
Global 70% Isopropyl Rubbing Alcohol Market Research Report 2025
Jun 12, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232